Our pan-HER candidate Sym013 is a novel drug candidate comprised of six different antibodies - two each targeting the EGFR, HER2 and HER3 receptors currently in Phase 1 clinical studies. 
 
Administration of Sym013 is associated with rapid elimination of all three targets and consequently lead to a total "horizontal" blockade of HER oncogenic signaling. 
 
The mechanism of action for Sym013 is associated with anti-tumor activities as evidenced in several preclinical models of epithelial tumors.